Continue Reading With Our 7-Day Free Trial
Imagine a company reporting encouraging cancer treatment results, only to watch its stock plunge nearly 18% in a single day. That is what happened to Moderna (NASDAQ: MRNA) on October 22, 2026. The Moderna Cancer Vaccine program was central to the market’s reaction.
Moderna and Merck (NYSE) are developing an experimental personalized cancer vaccine called intismeran autogene. It is designed to help prevent melanoma, a serious form of skin cancer, from returning after surgery.
The reported Phase 3 results showed a 42% lower relative risk of melanoma recurrence or death when the vaccine was combined with Merck’s Keytruda. This does not mean 42% fewer patients developed cancer or that 42% were cured.
Yet Moderna shares fell to $202.63 after clinical information surfaced ahead of a major medical conference.
So why did investors sell?
The answer involves leaked trial data, unusually high expectations, questions about the treatment’s long-term potential, and a stock valuation reflecting substantial future growth.
Moderna Cancer Vaccine: A Different Approach To Cancer Treatment
Most vaccines are designed to prevent infections. Moderna’s experimental cancer vaccine works differently. It is designed to help the immune system recognize cancer cells that may remain after surgery.
Doctors first analyze a patient’s tumor to identify its unique mutations. Moderna then uses that information to create a personalized mRNA treatment. The goal is to train immune cells to recognize proteins associated with that patient’s cancer.
The vaccine is being tested alongside Keytruda, an existing cancer immunotherapy. Keytruda helps immune cells attack cancer, while Moderna’s treatment aims to make those cells better at recognizing it.
The reported Phase 3 results showed a hazard ratio of 0.58. That translates into a 42% relative reduction in the risk of melanoma returning or death compared with Keytruda alone.
Importantly, this figure describes the relative risk over the study period. It does not mean that 42% of patients were cured or that everyone’s individual risk fell by 42 percentage points.
Moderna also reported earlier evidence that the treatment can trigger cancer-targeting immune responses. However, one detailed immune-cell analysis involved only seven patients. This provides additional context for the Moderna Cancer Vaccine program.
The clinical findings are encouraging, but the vaccine remains experimental. Regulatory approval and additional evidence are still necessary before it can become an established treatment.
Clinical Progress Is Encouraging Valuation Still Demands Commercial Proof
Moderna’s Phase 3 melanoma results showed a 42% lower relative risk of recurrence or death, yet shares fell approximately 18%. The divergence reflects a market weighing encouraging clinical progress against elevated expectations and a valuation that depends on future commercial success. Investors must assess whether the oncology pipeline can ultimately support that valuation.
Encouraging melanoma results and nine Phase 2 and 3 studies offer commercial opportunities if further evidence supports approval and broader oncology adoption.
Elevated sales multiples leave limited room for commercialization setbacks while Moderna remains loss-making and the vaccine’s long-term survival benefit remains unproven.
Follow subsequent survival analyses and regulatory developments to assess whether the observed recurrence benefit supports approval and a sustainable commercial opportunity.
Moderna’s clinical progress creates meaningful oncology potential, but its valuation already reflects substantial expectations. The investment case ultimately depends on regulatory progress, commercial execution, and whether future revenue and profitability can justify the premium to historical sales.
Why Moderna Crashed 18% Despite Encouraging Cancer Vaccine Results
The selloff followed an unusual sequence of events on October 22.
Ahead of the scheduled presentation at a major oncology conference, Oncology Central reportedly published clinical trial details prematurely. The article was withdrawn, but the information had already circulated across social media.
Conference organizers acknowledged the embargo breach and lifted the restriction on releasing the complete dataset that afternoon.
During the trading session, Moderna shares came under heavy selling pressure. By the close, the stock had fallen approximately 18% to $202.63, while Merck shares declined around 1.8%.
The reaction appeared surprising because the primary result exceeded several analysts’ expectations. UBS analyst Michael Yee had previously suggested that a hazard ratio of 0.65 could support a 10%–20% stock rally. Other analysts had also described results near or below 0.60 favorably.
But there was another factor: Moderna shares remained more than 500% higher for 2026, even after the decline, according to contemporary market reporting.
Such gains can leave little room for disappointment. Investors may sell when anticipated good news finally arrives, especially if they believe much of its value is already reflected in the share price.
This is commonly called a sell-the-news reaction. The Moderna Cancer Vaccine results arrived against this backdrop of elevated investor expectations.
The leak accelerated the market’s encounter with the results. It does not, by itself, establish why individual investors sold.
The Hidden Catch Behind Moderna’s Cancer Vaccine Results
The main Phase 3 result was positive. But investors were looking beyond the headline number.
The earlier Phase 2b study reported a recurrence-free survival hazard ratio of 0.51. The larger Phase 3 study reported 0.58. A lower hazard ratio indicates a greater relative reduction in risk, so some investors focused on that difference.
However, the studies differed in design, patient populations, and follow-up periods. The change from 0.51 to 0.58 does not prove the treatment became less effective.
Another result attracted attention. The Phase 3 trial showed a 38% relative reduction in the risk of distant recurrence or death. Although statistically significant, it fell short of some analysts’ expectations.
Timing matters, too.
During Moderna’s July earnings call, management explained that treatment benefits in the earlier study became more pronounced after approximately 12 months. The Phase 3 study required at least 18 months of follow-up.
Management also acknowledged that a commercially valuable treatment might not meet every early efficacy threshold. This was a discussion of trial design and potential outcomes, not a guarantee of commercial success.
These distinctions are important when interpreting the Moderna Cancer Vaccine results.
Overall survival data remain immature. A definitive survival advantage has therefore not yet been established.
Is Moderna’s Cancer Vaccine Still A Billion-Dollar Opportunity?
The melanoma results matter, but Moderna’s commercial ambitions extend beyond one type of cancer.
The company is working with Merck on nine Phase 2 and Phase 3 studies involving intismeran. These include melanoma, lung, kidney, and bladder cancers. Earlier-stage studies are also exploring pancreatic and gastric cancers.
Success in melanoma does not guarantee similar results elsewhere. Different cancers respond differently to immune-based treatments.
Manufacturing presents another challenge. Unlike conventional vaccines, each treatment must be customized using information from an individual patient’s tumor.
Moderna has been establishing a dedicated manufacturing facility in Massachusetts. Management believes it could support an initial commercial launch, subject to regulatory approval. Manufacturing readiness is therefore another consideration for the Moderna Cancer Vaccine program.
The financial picture also matters.
In the second quarter of 2026, Moderna generated $145 million in revenue and reported a $782 million net loss. Research and development expenses totaled $651 million.
The company ended June with $6.9 billion in cash and investments. It subsequently paid $950 million toward a litigation settlement.
Management projected year-end cash and investments of $4.7 billion to $5.2 billion.
Moderna therefore had substantial financial resources at midyear. However, regulatory reviews, competition, personalized manufacturing costs, and continued operating losses could affect future oncology profitability.
Clinical progress is real; the valuation still requires commercial proof.
Final Thoughts
Moderna’s October 22 selloff highlights an important distinction: positive medical results do not automatically produce positive stock returns.
The Phase 3 data showed a meaningful relative reduction in melanoma recurrence or death risk. However, regulatory approval remains pending, overall survival evidence is immature, and success in other cancers is uncertain.
Valuation makes these questions particularly relevant for the Moderna Cancer Vaccine investment thesis.
On October 22, 2026, Moderna’s last-twelve-month (LTM) enterprise-value-to-revenue multiple stood at 33.79x, while its LTM price-to-sales ratio was 36.31x.
At June 30, those multiples were 9.72x and 12.49x, respectively.
The increase does not mean Moderna’s stock price rose by the same proportion. Enterprise value incorporates debt and cash, while price-to-sales uses equity market value. Both multiples also depend on trailing revenue, which can change between reporting periods.
The October figures nevertheless indicate a substantially higher valuation relative to historical sales.
Earnings-based measures provide limited insight. Moderna’s October 22 LTM EV/EBITDA was negative 34.29x, while its LTM P/E was negative 25.30x. These reflect negative earnings measures and are unsuitable for conventional profitability-based comparisons.
The central question is whether future revenue growth and sustainable profitability can support Moderna’s elevated valuation, given the costs and uncertainties of commercializing its cancer pipeline.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
